Trial Profile
Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Bone metastases; Solid tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 12 May 2014 New trial record
- 11 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.